Intellectual Property India Publishes Patent Application for 'Methods For Treating Muscle Wasting And Bone Disease Using Novel Hybrid Actriib Ligand Trap Proteins' Filed by Alivegen Inc.

MUMBAI, India, Sept. 5 -- Intellectual Property India has published a patent application (202528078805 A) filed by Alivegen Inc., Grand Cayman, Cayman Islands, on Aug. 19, for 'methods for treating muscle wasting and bone disease using novel hybrid actriib ligand trap proteins.'

Inventor(s) include Han, Hq; and Zhou, Xiaolan.

The application for the patent was published on Sept. 5, under issue no. 36/2025.

According to the abstract released by the Intellectual Property India: "The present disclosure describes novel hybrid soluble ActRIIB-ECD polypeptides, which fully retain binding affinity for myostatin and activin A but demonstrate significantly reduced binding to BMPs, especially BMP-9. The novel compositions described herein can be used to prepare novel hybrid ActRIIB ligand trap proteins, which can be used for modulating the growth of muscle, bone, cartilage, fat, fibroblast, blood, and neuronal tissue to counteract muscle wasting, bone loss, anemia, inflammation, and fibrosis in a therapeutically meaningful manner. Because these novel next-generation myostatin/activin inhibitors are safer and more effective molecules than the currently available myostatin inhibitors, they are useful in a wide variety of clinical indications."

The patent application was internationally filed on Oct. 19, 2017, under International application No.PCT/US2017/057351.

Disclaimer: Curated by HT Syndication.